TWI810239B - Food composition for improvement or prevention of lifestyle-related diseases - Google Patents

Food composition for improvement or prevention of lifestyle-related diseases Download PDF

Info

Publication number
TWI810239B
TWI810239B TW108103346A TW108103346A TWI810239B TW I810239 B TWI810239 B TW I810239B TW 108103346 A TW108103346 A TW 108103346A TW 108103346 A TW108103346 A TW 108103346A TW I810239 B TWI810239 B TW I810239B
Authority
TW
Taiwan
Prior art keywords
fulvic acid
humic
food composition
acid
mineral
Prior art date
Application number
TW108103346A
Other languages
Chinese (zh)
Other versions
TW201934021A (en
Inventor
藤田隆司
詩依羅 涼子 金川
Original Assignee
日商風格與價值日本股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商風格與價值日本股份有限公司 filed Critical 日商風格與價值日本股份有限公司
Publication of TW201934021A publication Critical patent/TW201934021A/en
Application granted granted Critical
Publication of TWI810239B publication Critical patent/TWI810239B/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本發明係提供一種生活習慣病之改善或預防用食品組成物,其特徵係富里酸為有效成分;一種肝機能改善用食品組成物,其特徵係富里酸為有效成分;一種抗疲勞用食品組成物,其特徵係富里酸為有效成分;一種肌肉增強用食品組成物,其特徵係富里酸為有效成分;及一種粒線體激活劑,其特徵係富里酸為有效成分。 The present invention provides a food composition for improving or preventing lifestyle-related diseases, characterized in that fulvic acid is an active ingredient; a food composition for improving liver function, characterized in that fulvic acid is an active ingredient; a food composition for anti-fatigue A substance characterized by fulvic acid as an active ingredient; a food composition for muscle strengthening characterized by fulvic acid as an active ingredient; and a mitochondrial activator characterized by fulvic acid as an active ingredient.

Description

生活習慣病之改善或預防用食品組成物 Food composition for improvement or prevention of lifestyle-related diseases

本發明係關於生活習慣病之改善或預防用食品組成物、肝機能改善用食品組成物、抗疲勞用食品組成物、肌肉增強用食品組成物、及粒線體激活劑。 The present invention relates to a food composition for improving or preventing lifestyle-related diseases, a food composition for improving liver function, a food composition for anti-fatigue, a food composition for muscle strengthening, and a mitochondrial activator.

近年來,由於歐美化之飲食習慣,導致脂肪攝取量上升、高脂血症、高血壓、糖尿病、肥胖等之生活習慣病逐漸增加。一般而言,關於生活習慣病的發生及預後之要因,可列舉如,生活習慣、遺傳、環境等。並且,生活習慣可列舉如,飲食習慣、運動習慣、休養、抽煙、飲酒等。 In recent years, due to Westernized eating habits, lifestyle-related diseases such as increased fat intake, hyperlipidemia, hypertension, diabetes, and obesity have gradually increased. In general, factors for the occurrence and prognosis of lifestyle-related diseases include, for example, lifestyle habits, heredity, and environment. In addition, lifestyle habits include, for example, eating habits, exercise habits, rest, smoking, drinking, and the like.

腐植質,主要係在土壤中植物殘渣、微生物遺體等,其中之碳水化合物及蛋白質,在長年累月間被微生物分解,其分解產物縮合而成之聚合物。腐植質,係包含富里酸及腐植酸之無定形聚合物。腐植酸,係可溶於鹼不溶於酸之赤褐色或黑褐色無定形高分子有機酸。另一方面,富里酸,係可溶於鹼及酸之無定形高分子有機酸。腐植質,除了富里酸及腐植酸以外,亦已知包含有脂肪酸、有機酸、胺基酸、蛋白質、礦物質等。 Humic substances are mainly plant residues and microbial remains in the soil. The carbohydrates and proteins in them are decomposed by microorganisms over many years, and the decomposition products are condensed into polymers. Humic substances are amorphous polymers containing fulvic and humic acids. Humic acid is a reddish brown or dark brown amorphous high molecular organic acid that is soluble in alkali and insoluble in acid. On the other hand, fulvic acid is an amorphous polymer organic acid soluble in alkali and acid. Humic substances, in addition to fulvic acid and humic acid, are also known to contain fatty acids, organic acids, amino acids, proteins, minerals, etc.

如此之富里酸(FA:Fulvic acid)係從在於腐植質土壤之有機酸,根據印度之古典醫療:阿育吠陀(Ayurveda),係將未精製之腐葉土作為 「喜來芝(Shilajit)」使用。在一部份的美國、日本之佐賀縣等已觀察到含有富里酸之腐葉土的累積,產業上已日漸朝向富里酸的規格化。 Such fulvic acid (FA: Fulvic acid) is an organic acid derived from humus soil. According to the classical medical treatment of India: Ayurveda (Ayurveda), unrefined humus is used as "Shilajit" is used. Accumulation of leaf humus containing fulvic acid has been observed in some parts of the United States and Saga Prefecture in Japan, and the industry is increasingly moving towards the standardization of fulvic acid.

含有富里酸的喜來芝在健康上之優點,源自富含高濃度之富里酸,可作為口服之預防認知障礙、阿茨海默病、呼吸道感染症、癌症、重金屬毒性、濕疹、及缺氧症之用藥。然而,目前仍無佐證,且富里酸之作用機制亦完全未明。 The health benefits of shilajit containing fulvic acid are derived from the high concentration of fulvic acid. It can be used as an oral medicine to prevent cognitive impairment, Alzheimer's disease, respiratory tract infection, cancer, heavy metal toxicity, eczema, and Medication for hypoxia. However, there is still no supporting evidence, and the mechanism of action of fulvic acid is completely unknown.

又,關於腐植酸,例如,非專利文獻1中已報導其與抗炎症作用相關。 Also, regarding humic acid, for example, it has been reported in Non-Patent Document 1 that it is associated with an anti-inflammatory action.

【先前技術文獻】[Prior technical literature] 【非專利文獻】【Non-patent literature】

【非專利文獻1】Phytother Res. 2015 Jun;29(6):791-5 [Non-Patent Document 1] Phytother Res. 2015 Jun; 29(6): 791-5

本發明之目的在於提供一種食品組成物,其具有優渥生活習慣病之改善或預防作用、肝機能改善作用、抗疲勞作用、及肌肉增強作用,並且本發明目的在於提供一種粒線體激活劑。 The object of the present invention is to provide a food composition which has the effects of improving or preventing lifestyle-related diseases, improving liver function, anti-fatigue, and strengthening muscles, and the object of the present invention is to provide a mitochondrial activator.

本發明者為達上述目的而不斷深入研究之結果,發現富里酸 可促進外周組織對於醣類之攝取、具有肌肉分化效果、保護粒線體膜電位且使ATP消費系統活性化。粒線體之預存耗氧能力,被認為係粒線體機能一重要之方面,被定義為產生基礎ATP與其最大活性之間之差。細胞受到壓力時,維持細胞機能所必要之ATP增加,能量需求增加。具備越大之預存耗氧能力之細胞,可產生越多之ATP,從而克服包含氧化應激在內之更多壓力。進一步,使小鼠口服攝取富里酸,顯示出可抑制因高脂飲食導致之體重增加,此可表示其對於生活習慣病有顯著之效果。此外,關於小鼠之肝機能,由血液檢查結果可知,藉由富里酸可改善肝機能。 As a result of continuous in-depth research by the inventors in order to achieve the above-mentioned purpose, it was found that fulvic acid It can promote the uptake of carbohydrates in peripheral tissues, has the effect of muscle differentiation, protects the mitochondrial membrane potential and activates the ATP consumption system. Mitochondrial prestored oxygen consumption capacity, considered an important aspect of mitochondrial function, is defined as the difference between basal ATP production and its maximal activity. When cells are under stress, the ATP necessary to maintain cell function increases, and the energy demand increases. Cells with greater pre-stored oxygen-consuming capacity can generate more ATP and thus overcome more stress including oxidative stress. Furthermore, oral intake of fulvic acid in mice was shown to suppress weight gain due to a high-fat diet, which indicates that it has a significant effect on lifestyle-related diseases. In addition, with regard to the liver function of mice, it can be seen from the results of blood tests that the liver function can be improved by fulvic acid.

本發明,係基於此等知識,進一步反覆檢討而完成,提供以下生活習慣病之改善或預防用食品組成物、肝機能改善用食品組成物、抗疲勞用食品組成物、肌肉增強用食品組成物、及粒線體激活劑者。 The present invention is completed based on these knowledge and further repeated examinations, and provides the following food compositions for improving or preventing lifestyle-related diseases, food compositions for improving liver function, food compositions for anti-fatigue, and food compositions for strengthening muscles , and mitochondrial activators.

項1.一種生活習慣病之改善或預防用食品組成物,其特徵係富里酸為有效成分。 Item 1. A food composition for improving or preventing lifestyle-related diseases, characterized in that fulvic acid is an active ingredient.

項2.如項1所記載之食品組成物,其中,前述生活習慣病,係選自糖尿病、胰島素阻抗性、高脂血症、肥胖、脂肪肝、運動障礙症候群、肌肉減少症、及惡病體質所成群中至少1種。 Item 2. The food composition as described in Item 1, wherein the lifestyle-related disease is selected from the group consisting of diabetes, insulin resistance, hyperlipidemia, obesity, fatty liver, dyskinesia, sarcopenia, and cachexia At least 1 type in the constitution group.

項3.一種肝機能改善用食品組成物,其特徵係富里酸為有效成分。 Item 3. A food composition for improving liver function, characterized in that fulvic acid is an active ingredient.

項4.一種抗疲勞用食品組成物,其特徵係富里酸為有效成分。 Item 4. An anti-fatigue food composition characterized in that fulvic acid is an active ingredient.

項5.一種肌肉增強用食品組成物,其特徵係富里酸為有效成分。 Item 5. A food composition for muscle strengthening, characterized in that fulvic acid is an active ingredient.

項6.一種粒線體激活劑,其特徵係富里酸為有效成分。 Item 6. A mitochondrial activator characterized in that fulvic acid is an active ingredient.

項7.一種粒線體活性化用組成物,其特徵係富里酸為有效成分。 Item 7. A composition for activating mitochondria, characterized in that fulvic acid is an active ingredient.

項8.一種生活習慣病之改善或預防方法、肝機能改善方法、疲勞改善方法、肌肉增強方法、或粒線體活性化方法,其特徵係包含將富里酸之有效量對於哺乳動物給藥之步驟。 Item 8. A method for improving or preventing lifestyle-related diseases, a method for improving liver function, a method for improving fatigue, a method for strengthening muscles, or a method for activating mitochondria, which is characterized by comprising administering an effective amount of fulvic acid to mammals step.

項9.一種使用,其特徵係在生活習慣病之改善或預防用食品組成物、肝機能改善用食品組成物、抗疲勞用食品組成物、肌肉增強用食品組成物、或粒線體激活劑的製造中,富里酸的使用。 Item 9. A use characterized in that it is a food composition for improving or preventing lifestyle-related diseases, a food composition for improving liver function, a food composition for anti-fatigue, a food composition for muscle strengthening, or a mitochondrial activator In the manufacture of fulvic acid is used.

項10.一種使用,其特徵係作為生活習慣病之改善或預防劑、肝機能改善劑、抗疲勞劑、肌肉增強劑、或粒線體激活劑之富里酸的使用。 Item 10. A use characterized by use of fulvic acid as an agent for improving or preventing lifestyle-related diseases, an agent for improving liver function, an agent for anti-fatigue, an agent for strengthening muscles, or an agent for activating mitochondria.

項11.如項8所記載之方法、項9所記載之使用、或項10所記載之使用,其中,前述生活習慣病,係選自糖尿病、胰島素阻抗性、高脂血症、肥胖、脂肪肝、運動障礙症候群、肌肉減少症、及惡病體質所成群中至少1種。 Item 11. The method as described in Item 8, the use as described in Item 9, or the use as described in Item 10, wherein the aforementioned lifestyle-related disease is selected from diabetes, insulin resistance, hyperlipidemia, obesity, fat At least one of the groups of liver, dyskinesia, sarcopenia, and cachexia.

富里酸,具有顯著地優渥生活習慣病之改善或預防作用、肝機能改善作用、抗疲勞作用、肌肉增強作用、及粒線體活性化作用,故可有效作為生活習慣病之改善或預防用食品組成物、肝機能改善用食品組成物、抗疲勞用食品組成物、肌肉增強用食品組成物、及粒線體激活劑之有效成分。 Fulvic acid has remarkable effects of improving or preventing lifestyle-related diseases, improving liver function, anti-fatigue, strengthening muscles, and activating mitochondria, so it can be effectively used as a food for improving or preventing lifestyle-related diseases Composition, food composition for improving liver function, food composition for anti-fatigue, food composition for muscle strengthening, and active ingredient of mitochondrial activator.

【圖1】表示「腐植礦」(Humicle)之促進肌肉細胞攝取醣類作用之 圖表。GLUT抑制劑10μM(GLUT-I),0.1%腐植礦,1μM胰島素。數據係表示平均±S.E.M.。n=6 【Figure 1】Showing the effect of "Humicle" on promoting the uptake of carbohydrates by muscle cells chart. GLUT inhibitor 10μM (GLUT-I), 0.1% humic mineral, 1μM insulin. Data represent mean ± S.E.M. n=6

【圖2】表示藉由免疫組織化學所得腐植礦之肌肉分化促進作用之相片。 [ Fig. 2 ] Photographs showing the muscle differentiation-promoting effect of humic mineral obtained by immunohistochemistry.

【圖3】表示腐植礦對於肌肉細胞分化標記之影響之圖表。數據係表示平均±S.E.M.。n=6 [ Fig. 3 ] A graph showing the effect of humic minerals on muscle cell differentiation markers. Data represent mean ± S.E.M. n=6

【圖4】表示腐植礦之ATP消費促進作用之隨時間變化(上)與用量反應(下)之圖表。數據係表示平均±S.E.M.。n=6 [Fig. 4] A graph showing the time-dependent (top) and dosage response (bottom) of the ATP consumption-promoting effect of humic minerals. Data represent mean ± S.E.M. n=6

【圖5】表示藉由腐植礦所致粒線體膜電位之變化之相片。(A)控制組,(B)腐植礦0.1%,(C)放線菌素10μm [FIG. 5] Photographs showing changes in mitochondrial membrane potential caused by humic minerals. (A) control group, (B) humic mineral 0.1%, (C) actinomycin 10μm

【圖6】表示腐植礦所致粒線體膜電位亢進作用之圖。(左)載體,(右)腐植礦 [ Fig. 6 ] A diagram showing the action of increasing mitochondrial membrane potential by humic minerals. (Left) Carrier, (Right) Humic Mine

【圖7】表示將腐植礦對於小鼠給藥後經30~60分後之運動量之圖表。*P<0.05,vs.載體,N.S.;not significant,n=6 [ Fig. 7 ] A graph showing the amount of exercise 30 to 60 minutes after administration of humic mineral to mice. * P<0.05, vs. vehicle, NS; not significant, n=6

【圖8】表示餵食小鼠高脂肪飲食時因腐植礦所致體重減少效果之圖表。給予ND:normal diet(CRF-1;東方酵母工業股份有限公司(Oriental Yeast Co.,Ltd.)),HFD:high fat diet(HFD-32;日本克萊爾股份有限公司),HFD+腐植礦(與HFD-32混飼料)。數據係表示平均±S.E.M.。n=5 [ Fig. 8 ] A graph showing the effect of reducing body weight by humic minerals when mice were fed a high-fat diet. Give ND: normal diet (CRF-1; Oriental Yeast Co., Ltd.), HFD: high fat diet (HFD-32; Japan Claire Co., Ltd.), HFD+humic mineral (with HFD -32 mixed feed). Data represent mean ± S.E.M. n=5

【圖9】表示餵食小鼠高脂肪飲食時因腐植礦所致血液標記之影響之圖表。HFD(白管柱),HFD+腐植礦(黑管柱),數據係表示平均±S.E.M.。*P<0.05,**P<0.001,n=5 [ Fig. 9 ] A graph showing the effect of humic minerals on blood markers when mice were fed a high-fat diet. HFD (white tube column), HFD+humic ore (black tube column), the data represent mean±SEM. * P<0.05, ** P<0.001, n=5

【圖10】表示餵食小鼠高脂肪飲食之屍檢結果(A、C)及病理分析之 結果(B、D)之相片(餵食6週)。(A、B)肝臓,(C、D)附睾,比例尺:50μm [Figure 10] shows the autopsy results (A, C) and pathological analysis of mice fed a high-fat diet Photographs of results (B, D) (fed for 6 weeks). (A, B) Liver follicles, (C, D) Epididymis, scale bar: 50 μm

【圖11】表示脂肪細胞直徑(像素)之圖表。數據係表示平均±S.E.M.。 [ Fig. 11 ] A graph showing the diameter (pixel) of adipocytes. Data represent mean ± S.E.M.

【圖12】表示餵食小鼠高脂肪飲食6週後,進行葡萄糖耐量試驗之結果之圖表。數據係表示平均±S.E.M.。n=5 [ Fig. 12 ] A graph showing the results of a glucose tolerance test after mice were fed a high-fat diet for 6 weeks. Data represent mean ± S.E.M. n=5

【圖13】表示小鼠肌肉組織之ATP/ADP比率測定之結果(A)以及每肌肉勻漿蛋白之ATP及ADP量(B)之圖表。*P<0.05,vs.HFD group,n=4 [ Fig. 13 ] A graph showing the results of measurement of the ATP/ADP ratio of mouse muscle tissue (A) and the amounts of ATP and ADP per muscle homogenate protein (B). * P<0.05, vs. HFD group, n=4

【圖14】表示富里酸之ATP消費促進作用之用量反應之圖表。暴露30分後之數據。數據係表示平均±S.E.M.。n=8 [ Fig. 14 ] A graph showing the dose-response of the ATP consumption-promoting effect of fulvic acid. Data after 30 minutes of exposure. Data represent mean ± S.E.M. n=8

【圖15】表示富里酸之Flux Analyzer之分析結果之圖。n=7 [ Fig. 15 ] A graph showing the analysis results of fulvic acid by Flux Analyzer. n=7

【圖16】表示富里酸之Flux Analyzer之分析結果之圖。左欄表示載體,中央欄表示富里酸,右欄表示腐植礦。**P<0.001 vs載體control,n=7 [ Fig. 16 ] A graph showing the analysis results of fulvic acid by Flux Analyzer. The left column represents the carrier, the central column represents fulvic acid, and the right column represents humic minerals. ** P<0.001 vs carrier control, n=7

【圖17】表示腐植礦與標準物質之紅外吸收光譜之圖。 [ Fig. 17 ] A graph showing the infrared absorption spectra of humic minerals and standard substances.

【圖18】表示腐植礦與標準物質之三維螢光光譜之圖。 [ Fig. 18 ] A diagram showing three-dimensional fluorescence spectra of humic minerals and standard substances.

以下,詳細說明本發明。 Hereinafter, the present invention will be described in detail.

又,本說明書中「包含(comprise)」,係包含「本質上由...組成(essentially consist of)」之意義及「只由...組成(consist of)」之意義。 Also, "comprise" in this specification includes the meaning of "essentially consist of" and the meaning of "only consist of".

本發明之生活習慣病之改善或預防用食品組成物、肝機能改善用食品組成物、抗疲勞用食品組成物、肌肉增強用食品組成物、及粒線體激活劑,其特徵係將富里酸作為有效成分。 The food composition for improving or preventing lifestyle-related diseases, the food composition for improving liver function, the food composition for anti-fatigue, the food composition for muscle strengthening, and the mitochondrial activator of the present invention are characterized in that fulvic acid as an active ingredient.

富里酸,係在腐植質所含物質中,可溶於鹼及酸之無定形高 分子有機酸。富里酸之原料之腐植質,其產地、狀態等並無特別限制,可使用任意之腐植質。 Fulvic acid, which is contained in the substances contained in humic substances, is soluble in alkali and acid and has an amorphous high Molecular organic acids. The humic substance used as the raw material of fulvic acid is not particularly limited in terms of its origin and state, and any humic substance can be used.

如此之腐植質,可列舉例如,由美國猶他州埃默里縣之古代植物堆積層(頁岩層)所得人類頁岩(腐植質頁岩)。腐植質頁岩,係約7000~1億2700萬年前之含有多數營養素之肥沃的土壤不為變性為石油及煤碳,作為有機物殘存者。棲息在前述時代之植物,經冰河時期而埋沒至地底,藉由細菌等微生物而變化為泥炭蘚,在其上重複堆積新的有機物,並再次藉由細菌等分解,雖著時間的推移而形成堆積層者。形成之堆積層所含腐植質,係含有富里酸、腐植酸之有機高分子聚合物所成物質為主成分、及70種以上之微量礦物質。 Such humic substances include, for example, human shale (humic shale) obtained from ancient plant deposits (shale layers) in Emory County, Utah, USA. Humic shale is the fertile soil containing most nutrients from about 70 to 127 million years ago, which is not denatured into oil and coal, but remains as organic matter. The plants inhabiting the aforementioned era were buried underground during the Ice Age, transformed into sphagnum moss by microorganisms such as bacteria, and new organic matter was repeatedly accumulated on it, and decomposed by bacteria again, forming over time Stackers. The humic substances contained in the formed accumulation layer are mainly composed of organic polymers containing fulvic acid and humic acid, and more than 70 kinds of trace minerals.

從腐植質萃取富里酸之方法,並無特別限制,可使用各種習知的方法。萃取手段,可列舉例如:固液萃取、液液萃取、浸漬、浸出、煎出、環流萃取、超臨界流體萃取、微波萃取、混合攪拌等。萃取手段可1種單獨進行或將2種以上組合進行。 The method for extracting fulvic acid from humic substances is not particularly limited, and various known methods can be used. Extraction means include, for example: solid-liquid extraction, liquid-liquid extraction, immersion, leaching, decoction, circulation extraction, supercritical fluid extraction, microwave extraction, mixing and stirring, and the like. The extraction means may be performed alone or in combination of two or more.

藉由將腐植質與萃取溶劑混合萃取富里酸之情形,萃取溶劑,可列舉例如:水(例如,蒸餾水、離子交換水、逆滲透壓水等);醇類(例如,甲醇、乙醇、丙醇等);此等之混合液等。該萃取操作之萃取時間、萃取溫度、萃取溶劑之pH等,可考慮萃取效率等而適宜地設定。 In the case of extracting fulvic acid by mixing humic substances with an extraction solvent, the extraction solvent can include, for example: water (for example, distilled water, ion-exchanged water, reverse osmosis water, etc.); alcohols (for example, methanol, ethanol, propanol etc.); mixtures thereof, etc. The extraction time, extraction temperature, pH of the extraction solvent, and the like in the extraction operation can be appropriately set in consideration of extraction efficiency and the like.

腐植質之萃取物,為了去除不須物及除菌,可進行過濾。過濾之手段,並無特別限制,可藉由常規方法進行。 The extract of humic substances can be filtered in order to remove unnecessary substances and sterilize. The means of filtration is not particularly limited, and can be performed by conventional methods.

腐植質之萃取物,可進一步進行富里酸的分離或純化之處理。如此之分離或純化處理,可列舉例如:濃縮、減壓濃縮、蒸餾、分餾、 相轉移、溶劑萃取、結晶化、再結晶、層析等。此等之方法可1種單獨進行或將2種以上組合進行。 The extract of humic substances can be further processed for separation or purification of fulvic acid. Such separation or purification treatment includes, for example, concentration, concentration under reduced pressure, distillation, fractional distillation, Phase transfer, solvent extraction, crystallization, recrystallization, chromatography, etc. These methods may be performed alone or in combination of two or more.

富里酸,可使用未分離或純化狀態者(粗萃取物等),亦可使用分離純化完成者。 Fulvic acid can be used in an unseparated or purified state (crude extract, etc.), or can be used in a separated and purified form.

此外,富里酸,可在游離狀態或鹽狀態下使用。富里酸之鹽類,可列舉例如:鈉、鎂、鉀、鈣、鋁等之無機鹽;與甲胺、乙胺、乙醇胺等之有機鹽基連接之鹽;與賴胺酸、鳥胺酸、精胺酸等之鹼性胺基酸連接之鹽及銨鹽。該鹽,可係酸式鹽,相關之鹽,具體而言,可列舉如:鹽酸、氫溴酸、氫碘酸、硫酸、硝酸、磷酸等之無機酸;甲酸、乙酸、丙酸、草酸、丙二酸、蘋果酸、酒石酸、富馬酸、琥珀酸、乳酸、馬來酸、檸檬酸、甲磺酸、乙烷磺酸等之有機酸;與天冬胺酸、谷胺酸等之酸性胺基酸連接之酸式鹽。富里酸,亦包含與水合物、溶劑化、礦物質類絡合者等。 In addition, fulvic acid can be used in free state or salt state. Salts of fulvic acid include, for example: inorganic salts of sodium, magnesium, potassium, calcium, aluminum, etc.; salts linked to organic bases such as methylamine, ethylamine, and ethanolamine; Basic amino acid-linked salts and ammonium salts of arginine and the like. The salt can be an acid salt, and related salts, specifically, include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; formic acid, acetic acid, propionic acid, oxalic acid, Organic acids such as malonic acid, malic acid, tartaric acid, fumaric acid, succinic acid, lactic acid, maleic acid, citric acid, methanesulfonic acid, ethanesulfonic acid; acids with aspartic acid, glutamic acid, etc. Acid salt of amino acid linkage. Fulvic acid also includes those complexed with hydrates, solvates, and minerals.

富里酸之形態,並無特別限制,可列舉例如:粉末狀、顆粒狀、固形狀、溶液狀、懸浮液狀、乳濁液狀、濃縮液狀、漿態狀等。 The form of fulvic acid is not particularly limited, and examples thereof include powder, granule, solid, solution, suspension, emulsion, concentrated liquid, and slurry.

富里酸,可使用自家調製品、抑或市售品任一者。富里酸之市售品,可列舉例如:風格與價值日本股份有限公司所販售之「腐植礦(Humicle,商標)HC富里酸粉末」等。該腐植礦所含富里酸,FT-IR法之紅外線吸收光譜在波長3362、2875、1675、1559、1360、1200、1047及835cm-1有紅外線吸收高峰(參照日本特許第6120342號公報)。 For fulvic acid, you can use your own preparations or commercially available products. Commercial products of fulvic acid include, for example, "Humicle (trademark) HC fulvic acid powder" sold by Style and Value Japan Co., Ltd. The fulvic acid contained in the humic ore has infrared absorption peaks at wavelengths of 3362, 2875, 1675, 1559, 1360, 1200, 1047 and 835 cm -1 in the infrared absorption spectrum of the FT-IR method (refer to Japanese Patent No. 6120342).

本發明之粒線體激活劑,亦包含食品組成物之意義。 The mitochondrial activator of the present invention also includes the meaning of food composition.

食品組成物包含哺乳動物(包含人類)可攝取之任何飲食品,可列舉例如:乳製品;發酵食品(優格、起司等);飲料類(咖啡、果汁、 可可亞、茶飲料、運動飲料、如營養飲料之清涼飲料、乳飲料、乳酸菌飲料、含乳酸菌飲料、優格飲料、碳酸飲料、如日本酒、洋酒、水果酒之酒等);抹醬類(卡士達奶油等);抹醬類(果醬等);西式甜點類(巧克力、甜甜圈、派、奶油泡芙、口香糖、軟糖、果凍、糖果、餅乾、蛋糕、布丁、比司吉等);冰甜點類(冰淇淋、冰糖果、冰霜等);食品類(咖哩、牛丼、雜炊、味噌湯、湯、肉醬、義大利麵、漬物、沾醬、火腿、香腸、培根等);調味料類(沙拉醬、香鬆、鮮味調味料、湯塊、味噌、醬油、醬料、番茄醬、蠔油等)等。 Food composition includes any food and drink that mammals (including humans) can ingest, for example: dairy products; fermented foods (yogurt, cheese, etc.); beverages (coffee, fruit juice, Cocoa, tea drinks, sports drinks, refreshing drinks such as nutrition drinks, milk drinks, lactic acid bacteria drinks, drinks containing lactic acid bacteria, yogurt drinks, carbonated drinks, such as Japanese wine, foreign wine, fruit wine, etc.); Starch cream, etc.); Spreads (jams, etc.); Western-style desserts (chocolate, donuts, pies, cream puffs, chewing gum, fudge, jelly, candy, biscuits, cakes, puddings, biscuits, etc.) ; Ice desserts (ice cream, ice candy, ice cream, etc.); food (curry, beef bowl, miso soup, soup, meat sauce, pasta, pickles, dipping sauce, ham, sausage, bacon, etc.); Seasonings (salad dressing, pine, umami seasoning, soup cubes, miso, soy sauce, sauces, ketchup, oyster sauce, etc.), etc.

食品組成物之製法亦無特別限定,可根據適合之習知的方法。 The preparation method of the food composition is also not particularly limited, and may be based on a suitable known method.

食品組成物,可列舉如:健康食品、機能性食品、營養補助食品、營養補充品、保健用食品、特定保健用食品、營養機能食品、機能性表示食品等。作為營養補充品使用時之劑量單位形式並無特別限定可適宜地選擇,可列舉例如:錠劑、膠囊劑、顆粒劑、液劑、散劑等。 The food composition includes, for example, health food, functional food, nutritional supplement food, nutritional supplement, health food, food for specific health use, nutritional functional food, functionally indicated food, and the like. The dosage unit form when used as a nutritional supplement is not particularly limited and can be appropriately selected, and examples thereof include tablets, capsules, granules, liquids, powders, and the like.

此外,食品組成物,亦包含賦予生活習慣病之改善或預防作用、肝機能改善作用、抗疲勞作用、肌肉增強作用、及粒線體活性化作用之添加劑之意義。 In addition, the food composition also includes the meaning of an additive imparting an effect of improving or preventing lifestyle-related diseases, effect of improving liver function, effect of anti-fatigue, effect of strengthening muscles, and effect of activating mitochondria.

食品組成物,因應必要,可配合賦形劑,維他命類,礦物質類、黃酮類、醌類、多酚類、胺基酸、核酸、必須脂肪酸、清涼劑、結合劑、增甜劑、崩解劑、滑潤劑、染色劑、香料、安定劑、防腐劑、緩釋調整劑、界面活性劑、光澤劑、溶解劑、濕潤劑等。 Food composition, if necessary, can be mixed with excipients, vitamins, minerals, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants Debonding agent, lubricant, dyeing agent, perfume, stabilizer, preservative, sustained release regulator, surfactant, gloss agent, solvent, wetting agent, etc.

食品組成物所含富里酸之比例,可列舉例如:0.01~99質量 %、1~80質量%、10~70質量%等。 The proportion of fulvic acid contained in the food composition, for example: 0.01~99% by mass %, 1~80 mass%, 10~70 mass%, etc.

食品組成物之攝取量,可因應攝取者之體重、年齡、性別、症狀等種種條件而適宜地設定。 The intake amount of the food composition can be appropriately set according to various conditions such as the body weight, age, sex, and symptoms of the ingester.

如後述之試驗例所示,本發明者們,發現富里酸可促進外周組織對於醣類之攝取、具有肌肉分化效果、保護粒線體膜電位且使ATP消費系統活性化。亦即,促進外周組織對於醣類的攝取,可期待針對糖尿病的改善或預防效果。此外,具有肌肉分化效果,可期待針對肌肉增強作用、及肌肉減少症、運動障礙症候群等的改善或預防作用。保護粒線體膜電位且使ATP消費系統活性化,可期待改善粒線體老化及疲勞回復作用。 As shown in the test examples described below, the present inventors found that fulvic acid can promote the uptake of carbohydrates in peripheral tissues, has muscle differentiation effects, protects mitochondrial membrane potential, and activates the ATP consumption system. That is, the improvement or preventive effect against diabetes can be expected by promoting the uptake of carbohydrates in peripheral tissues. In addition, it has a muscle differentiation effect, and can be expected to improve or prevent muscle strengthening effects, sarcopenia, dyskinesias, and the like. Protecting the mitochondrial membrane potential and activating the ATP consumption system can be expected to improve mitochondrial aging and fatigue recovery.

再者,發現藉由使小鼠口服富里酸,可抑制高脂肪飲食所導致的體重增加,故可期待針對生活習慣病的改善或預防作用。此外,在小鼠之葡萄糖耐量試驗,可觀察到藉由攝取富里酸而降低血糖值,可期待針對胰島素阻抗性之效果。進一步,關於小鼠的肝機能及脂質代謝之血液檢查結果,可觀察到藉由富里酸而有肝機能及脂質代謝的改善。進一步,富里酸可活化食欲,使肌肉組織的代謝亢進(ATP/ADP比),可期待針對惡病體質的改善或預防作用。此外,由於粒線體之機能得到亢進,故可期待粒線體之活性化作用。 Furthermore, it was found that by orally administering fulvic acid to mice, body weight gain caused by a high-fat diet can be suppressed, so an improvement or preventive effect against lifestyle-related diseases can be expected. In addition, in the glucose tolerance test of mice, it was observed that the intake of fulvic acid lowered the blood sugar level, and the effect on insulin resistance can be expected. Furthermore, regarding the blood test results of liver function and lipid metabolism in mice, it was observed that liver function and lipid metabolism were improved by fulvic acid. Furthermore, fulvic acid can activate appetite and increase the metabolism of muscle tissue (ATP/ADP ratio), and can be expected to improve or prevent cachexia constitution. In addition, since the function of mitochondria is enhanced, activation of mitochondria can be expected.

因此,富里酸具有顯著的優渥生活習慣病之改善或預防作用、肝機能改善作用、抗疲勞作用、肌肉增強作用、及粒線體活性化作用,故可合適地作為生活習慣病之改善或預防用食品組成物、肝機能改善用食品組成物、抗疲勞用食品組成物、肌肉增強用食品組成物、及粒線體激活劑之有效成分使用。 Therefore, fulvic acid has significant effects of improving or preventing lifestyle-related diseases, improving liver function, anti-fatigue, strengthening muscles, and activating mitochondria, so it can be suitable for improving or preventing lifestyle-related diseases. Food composition, food composition for improving liver function, food composition for anti-fatigue, food composition for muscle strengthening, and active ingredient of mitochondrial activator.

在此,生活習慣病,並無特別限制,可列舉例如;糖尿病、胰島素阻抗性、高脂血症、高血壓、肥胖、脂肪肝、運動障礙症候群、肌肉減少症、惡病體質(cachexia)(惡液質)等。 Here, the lifestyle-related disease is not particularly limited, and examples thereof include diabetes, insulin resistance, hyperlipidemia, hypertension, obesity, fatty liver, dyskinesia, sarcopenia, and cachexia ( dyscrasias), etc.

本說明書中,肌肉增強,係包含肌肉量增加、抑制(防止)肌肉量之減低、回復所減低之肌肉量等意義。 In this specification, muscle enhancement includes the meanings of increasing muscle mass, inhibiting (preventing) the decrease of muscle mass, and recovering the decreased muscle mass.

此外,富里酸,由於係天然由来成分,故安全性高。 In addition, fulvic acid is highly safe because it is a natural ingredient.

【實施例】【Example】

以下,為了進一步詳細說明本發明而列舉實施例。惟,本發明並未限定為此等實施例等。 Hereinafter, examples are given in order to further describe the present invention in detail. However, the present invention is not limited to these Examples and the like.

動物 animal

若無特別記載,則係使用C57BL/6N公小鼠進行以下實驗。8週齡之C57BL/6N公小鼠係從清水實驗材料股分有限公司(Kyoto,Japan)購入。 Unless otherwise specified, C57BL/6N male mice were used for the following experiments. 8-week-old C57BL/6N male and mouse lines were purchased from Shimizu Laboratory Materials Co., Ltd. (Kyoto, Japan).

試驗例1:體外試驗(腐植礦之肌肉細胞之醣類攝取促進作用) Test Example 1: In Vitro Test (Promoting Effect of Humic Mineral on Carbohydrate Uptake in Muscle Cells)

根據常規方法,將C2C12細胞分化。置換至未含葡萄糖之介質,在GLUT抑制劑存在下或非存在下放置30分鐘後,藉由0.1%腐植礦或胰島素刺激。葡萄糖的攝取,係使用Glucose Uptake-Glo(商標)Assay(Promega,Madison,WI),測定冷發光活性。 According to conventional methods, C2C12 cells were differentiated. Replaced to glucose-free medium, after 30 minutes in the presence or absence of GLUT inhibitors, stimulated by 0.1% humic mineral or insulin. Glucose uptake was measured using Glucose Uptake-Glo (trademark) Assay (Promega, Madison, WI) to measure luminescent activity.

結果如圖1所示。由圖1可知,雖藉由胰島素可促進攝取醣類,惟0.1%腐植礦較胰島素可更強力地促進醣類攝取。此外,其作用有一部分係介由葡萄糖轉運蛋白,藉由GLUT-I之議制試驗可得知。 The result is shown in Figure 1. It can be seen from Figure 1 that although insulin can promote the intake of carbohydrates, 0.1% humic mineral can promote the intake of carbohydrates more strongly than insulin. In addition, part of its role is mediated by glucose transporter, which can be known by the preparation test of GLUT-I.

試驗例2:體外試驗(腐植礦之肌肉分化促進作用) Test Example 2: In vitro test (muscle differentiation promoting effect of humic mineral)

根據常規方法,將C2C12細胞分化。藉由0.1%腐植礦刺激,並藉由MHC(Myosin heavy chain)抗體(mouse monoclonal MF20 antibody(Developmental Hybridoma Bank,Iowa City,IA))進行染色。 According to conventional methods, C2C12 cells were differentiated. Stimulated by 0.1% humic mineral, and stained by MHC (Myosin heavy chain) antibody (mouse monoclonal MF20 antibody (Developmental Hybridoma Bank, Iowa City, IA)).

結果如圖2所示。由圖2可知,藉由0.1%腐植礦可使MHC抗體陽性反應被明確誘導。亦即,0.1%腐植礦可促進肌肉分化。 The result is shown in Figure 2. It can be seen from Figure 2 that the positive reaction of MHC antibody can be clearly induced by 0.1% humic mineral. That is, 0.1% humic mineral can promote muscle differentiation.

將小鼠橫紋肌肉來源細胞C2C12接種至6孔盤,使腐植礦之終濃度為0.1%,以分化介質進行培養5天。每隔日進行介質交換。根據常規方法調製total RNA,進行qPCR分析。 Mouse striated muscle-derived cells C2C12 were inoculated into a 6-well plate, and the final concentration of humic mineral was 0.1%, and cultured with differentiation medium for 5 days. Media exchange was performed every other day. Prepare total RNA according to conventional methods and perform qPCR analysis.

結果如圖3所示。由圖3可知,0.1%腐植礦可抑制初期分化標記之發現,並可誘導後期分化標記之MCK(肌肉肌酸激酶)。 The result is shown in Figure 3. It can be seen from Figure 3 that 0.1% humic mineral can inhibit the discovery of early differentiation markers and induce late differentiation markers MCK (muscle creatine kinase).

試驗例3:體外試驗(腐植礦之ATP消費促進作用) Test Example 3: In Vitro Test (Promoting Effect of Humic Mineral on ATP Consumption)

將小鼠橫紋肌肉來源細胞C2C12接種1.25×104 cells/well之細胞數至96孔盤,使腐植礦終濃度為0.1%,伴隨時間推移測定細胞內ATP含量。在圖4所示時間時使細胞可溶化,使用ENLITEN(商標)ATP Assay System(Promega,Madison,WI)以20/20n Luminometer(Turner BioSystems,Sunnyvale,CA)測定。此外,亦測定腐植礦之6小時後之濃度依存ATP消費亢進作用。 Mouse striated muscle-derived cells C2C12 were inoculated into 96-well plates at a rate of 1.25×10 4 cells/well, so that the final concentration of humic minerals was 0.1%, and the ATP content in the cells was measured over time. Cells were lysed at the times indicated in Figure 4, as determined using the ENLITEN (trademark) ATP Assay System (Promega, Madison, WI) with a 20/20n Luminometer (Turner BioSystems, Sunnyvale, CA). In addition, the concentration-dependent ATP consumption hyperactivity of humic minerals after 6 hours was also determined.

結果如圖4所示。由圖4可知,藉由0.1%腐植礦可驅動ATP消費系統。雖數據未表示,但各濃度之腐植礦皆未顯示出細胞毒性。 The result is shown in Figure 4. It can be seen from Figure 4 that the ATP consumption system can be driven by 0.1% humic ore. Although the data is not shown, the humic minerals at various concentrations did not show cytotoxicity.

試驗例4:體外試驗(腐植礦之粒線體之膜電位亢進作用) Test Example 4: In Vitro Test (Membrane Potential Hyperactivity of Humic Ore Mitochondria)

將C2C12細胞接種1×105 cells/well之細胞數至48孔盤,使腐植礦終濃度為0.1%,對於24小時後之粒線體膜電位,使用JC-1色素觀察。 C2C12 cells were inoculated into a 48-well plate at 1×10 5 cells/well, and the final concentration of humic mineral was 0.1%. The mitochondrial membrane potential after 24 hours was observed with JC-1 pigment.

結果如圖5所示。由圖5可知,0.1%腐植礦在24小時候未影響粒線體膜電位,而抗癌劑知放線菌素則有影響。 The result is shown in Figure 5. It can be seen from Figure 5 that 0.1% humic mineral did not affect the mitochondrial membrane potential after 24 hours, but the anticancer agent actinomycin did.

將C2C12細胞接種,使腐植礦終濃度為0.1%,對於48小時後之粒線體膜電位,使用Muse(商標)Mitopotential Assay Kit(EMD Millipore Corp.,Darmstadt,Germany)測定。 C2C12 cells were inoculated so that the final humic mineral concentration was 0.1%, and the mitochondrial membrane potential after 48 hours was measured using the Muse (trademark) Mitopotential Assay Kit (EMD Millipore Corp., Darmstadt, Germany).

結果如圖6所示。由圖6可知,藉由0.1%腐植礦可使粒線體膜電位亢進。 The result is shown in Figure 6. It can be seen from Figure 6 that the mitochondrial membrane potential can be increased by 0.1% humic mineral.

試驗例5:體內試驗(腐植礦之口服導致小鼠的行動變化) Test Example 5: In vivo test (oral changes in behavior of mice caused by oral administration of humic minerals)

以相機對於直徑20cm之圓筒內之小鼠進行行動掃描(Smart3.0系統,Bioresearch Center,Aichi,Japan)。使ddY系小鼠及摘出腎上腺之ADX ddY系小鼠口服PBS 200μL(載體)、腐植礦100mg/200μL,觀察其90分鐘之行動。比較行動最為差異之30~60分之時間區間的自發運動量。 The mice in a cylinder with a diameter of 20 cm were scanned with a camera (Smart3.0 system, Bioresearch Center, Aichi, Japan). Oral administration of 200 μL of PBS (vehicle) and 100 mg/200 μL of humic minerals to ddY mice and ADX ddY mice from which the adrenal glands were removed was observed for 90 minutes. Compare the amount of spontaneous exercise in the 30-60th time period when the action is most different.

結果如圖7所示。由圖7可知,藉由0.1%腐植礦可驅動ATP消費系統,此外,使交感神經系統活性化之可能性極高。活性化交感神經系統時,會降低腸的蠕動運動,從而抑制排便。在此等檢討期間,排便方面,腐植礦給藥群有減少之傾向。 The result is shown in Figure 7. It can be seen from Figure 7 that the ATP consumption system can be driven by 0.1% humic mineral, and the possibility of activating the sympathetic nervous system is extremely high. When the sympathetic nervous system is activated, the peristaltic movement of the bowel is reduced, thereby inhibiting defecation. During these review periods, in terms of defecation, the humic ore-dosed groups tended to decrease.

試驗例6:體內試驗(腐植礦之口服對小鼠的影響) Test Example 6: In vivo test (the effect of oral administration of humic minerals on mice)

對於小鼠給藥Normal diet:ND、High fat diet:HFD及HFD與2%腐植礦之混合飼料,伴隨時間推移測定體重。 Normal diet: ND, High fat diet: HFD, and a mixed feed of HFD and 2% humic ore were administered to mice, and body weight was measured over time.

結果如圖8所示。由圖8可知,藉由將HFD(高脂肪飲食)與2%腐植礦配合,可抑制體重增加。雖圖式未表示,但飼料的攝取量,與2%腐植礦之混合飼料顯示有增加的傾向。因此,體重變化,並非混合腐植礦之 飼料會導致攝取量降低。由於反而會增加約2倍的攝取量,而即使攝取量增加仍可得到體重減少,故可推論腐植礦具有新陳代謝促進效果。 The result is shown in Figure 8. As can be seen from FIG. 8, weight gain can be suppressed by combining HFD (high-fat diet) with 2% humic mineral. Although not shown in the graph, the intake of feed showed a tendency to increase with the mixed feed of 2% humic mineral. Therefore, the weight change is not the result of mixing humic minerals. Feed will result in lower intake. On the contrary, it will increase the intake by about 2 times, and even if the intake increases, weight loss can still be obtained, so it can be inferred that humic minerals have a metabolism-promoting effect.

將HFD、及HFD與2%腐植礦之混合飼料對於小鼠給藥,切開尾部採取血液。使用Nipro血糖自己測定器測定血糖值。藉由血細胞比容管式離心機將所採取之血液進行血清分離。使用萊維斯(商標)胰島素-小鼠-T(FUJIFILM Wako Pure Chemical Corporation,Osaka,Japan),Mouse Adiponectin/Acrp30 Quantikine ELISA Kit(R&D systems,Minneapolis,MN)分別測定血漿中之胰島素、脂聯素濃度。 HFD, and a mixed feed of HFD and 2% humic mineral were administered to the mice, and the tail was cut to collect blood. Use the Nipro blood glucose self-monitoring device to measure the blood glucose value. The collected blood was subjected to serum separation by a hematocrit tube centrifuge. Use Levis (trademark) insulin-mouse-T (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), Mouse Adiponectin/Acrp30 Quantikine ELISA Kit (R&D systems, Minneapolis, MN) to measure insulin and adiponectin in plasma respectively concentration.

結果如圖9所示。由圖9可知,0.1%腐植礦可抑制活體的血糖值上升,預測會產生對於胰臟有益之效果,可改善脂肪組織之機能。 The result is shown in Figure 9. It can be seen from Figure 9 that 0.1% humic mineral can inhibit the rise of blood sugar level in the living body, and it is predicted that it will have a beneficial effect on the pancreas and improve the function of adipose tissue.

對於小鼠給藥ND、HFD及HFD與2%腐植礦之混合飼料持續6週,屍檢結果如圖10所示。肝臟及附睾組織重量,較HFD有顯著地增加,與2%腐植礦配合之HFD之組織重量增加與HFD相較下較低(A及C)。 For mice administered with ND, HFD and the mixed feed of HFD and 2% humic mineral for 6 weeks, the autopsy results are shown in Fig. 10 . The tissue weight of liver and epididymis increased significantly compared with HFD, and the tissue weight increase of HFD combined with 2% humic mineral was lower than that of HFD (A and C).

以10%(w/v)多聚甲醛將肝臟及附睾組織固定化,嵌入石蠟塊。使用切片機(Leica Biosystems,Wetzlar,Germany)將此塊體切成薄片。以蘇木精及伊紅將切片(5μm厚)染色,使用光學顯微鏡觀察。結果如圖10之B及D所示。肝臟及附睾組織之脂肪細胞徑之任一者,皆藉由HFD增加,惟與2%腐植礦配合之HFD則較為減少。 The liver and epididymis were fixed with 10% (w/v) paraformaldehyde and embedded in paraffin blocks. The block was sliced into thin slices using a microtome (Leica Biosystems, Wetzlar, Germany). Sections (5 μm thick) were stained with hematoxylin and eosin, and observed using an optical microscope. The results are shown in B and D of Fig. 10 . Any of the fat cell diameters of the liver and epididymis was increased by HFD, but the HFD combined with 2% humic mineral was relatively decreased.

附睾組織之脂肪組織HE染色結果,係使用顯微鏡用成像軟體cellSens(奧林巴斯股份有限公司)測定。各組分別從5匹得到組織樣品,將6斷面(6切片)染色。計測5視野中之1視野中30細胞。結果如圖11所示。脂肪細胞徑,雖因HFD而增加,但與2%腐植礦配合之HFD則會減少。 The results of HE staining of adipose tissue of epididymis tissue were determined using the imaging software cellSens (Olympus Co., Ltd.) for microscopy. For each group, tissue samples were obtained from 5 pieces, and 6 sections (6 sections) were stained. 30 cells in one field of view among the five fields of view were counted. The result is shown in Figure 11. Although the fat cell diameter increases with HFD, it will decrease with HFD combined with 2% humic mineral.

試驗例7:體內試驗(小鼠之葡萄糖耐量試驗) Test Example 7: In vivo test (glucose tolerance test in mice)

對於小鼠進行葡萄糖耐量試驗(OGTT:oral glucose tolerance test)之結果如圖12所示。與上述相同,藉由分別餵食各種飼料持續6週,口服給藥之300mg/ml葡萄糖100μl而進行,伴隨時間測定上述血糖值。其結果,最高血糖值係較0.1%腐植礦為低,此外葡萄糖耐量60分以後,血糖值的降低會因0.1%腐植礦而改善。此外,對於II型糖尿病模型之KK-Ay小鼠亦進行同樣實驗,藉由口服給藥腐植礦,可確認到體重減少及平常時血糖值降低。 The results of the glucose tolerance test (OGTT: oral glucose tolerance test) performed on mice are shown in FIG. 12 . In the same manner as above, each of the feeds was fed for 6 weeks, and 100 μl of 300 mg/ml glucose was orally administered, and the blood sugar level was measured over time. As a result, the highest blood sugar level is lower than that of 0.1% humic ore. In addition, after glucose tolerance of 60 points, the decrease of blood sugar level will be improved by 0.1% humic ore. In addition, the same experiment was performed on KK-Ay mice, which are a type II diabetes model, and body weight loss and normal blood sugar levels were reduced by oral administration of humic minerals.

試驗例8:體內試驗(小鼠之肝機能及脂質代謝之相關血液檢查) Test Example 8: In vivo test (blood tests related to liver function and lipid metabolism in mice)

對於小鼠給藥高脂肪飲食6週,小鼠之肝機能及脂質代謝之相關血液檢查結果如表1所示。血液係藉由心臟血液採樣而進行,藉由離心而得到血清。 Table 1 shows the blood test results of the liver function and lipid metabolism of the mice administered a high-fat diet for 6 weeks. Blood was obtained by sampling cardiac blood, and serum was obtained by centrifugation.

Figure 108103346-A0202-12-0016-1
Figure 108103346-A0202-12-0016-1

數據係表示平均±S.E.M.。n=5 Data represent mean ± S.E.M. n=5

AST、ALT、ALP、LDH、ChE值,係表示肝機能。與ND群相比,HFD群之肝機能惡化,惟將HFD與0.1%腐植礦混飼料,則確認到可大幅改善肝機能。與ND群比較,HFD群之中性脂肪(TG)、LDL-C值,確認到大幅惡化。相對於此,將HFD與0.1%腐植礦混飼料,則可確認到大幅改善脂質代謝。 AST, ALT, ALP, LDH, ChE values represent liver function. Compared with the ND group, the liver function of the HFD group deteriorated, but it was confirmed that the liver function could be greatly improved when HFD was mixed with 0.1% humic ore. Compared with the ND group, the neutral fat (TG) and LDL-C values of the HFD group were significantly deteriorated. On the other hand, when HFD was mixed with 0.1% humic mineral, it was confirmed that the lipid metabolism was greatly improved.

試驗例9:體內試驗(ATP/ADP比率測定) Test Example 9: In vivo test (ATP/ADP ratio measurement)

將1mL PBS中之小鼠肌肉組織勻漿進行離心(4℃,15,000rpm,5min)。對於5μL之上清液,使用ADP/ATP Assay kit(Sigma-Aldrich,MO,USA)藉由20/20n Luminometer測定冷發光。此外,每96孔盤之1孔150μL之working reagent添加15μL之上清液。37℃下培養15分鐘後,使用Protein Assay Bicichoninate Kit(Nacalai Tesque,Kyoto,Japan)藉由Model 680 Microplate Reader(Bio-Rad Laboratories)測定570nm之吸光值。 The homogenate of mouse muscle tissue in 1 mL of PBS was centrifuged (4° C., 15,000 rpm, 5 min). For 5 μL of supernatant, luminescence was measured by 20/20n Luminometer using ADP/ATP Assay kit (Sigma-Aldrich, MO, USA). In addition, 15 μL of supernatant was added to 150 μL of working reagent in 1 well of a 96-well plate. After incubating at 37° C. for 15 minutes, the absorbance at 570 nm was measured with a Model 680 Microplate Reader (Bio-Rad Laboratories) using the Protein Assay Bicichoninate Kit (Nacalai Tesque, Kyoto, Japan).

結果如圖13所示。由圖13中肌肉組織中之ATP/ADP比,可知腐植礦可使新陳代謝活性化。 The result is shown in Figure 13. From the ATP/ADP ratio in muscle tissue in Figure 13, it can be known that humic minerals can activate metabolism.

試驗例10:富里酸之效果 Test Example 10: Effect of Fulvic Acid

藉由與試驗例3相同的方法測定富里酸之濃度依存性ATP消費亢進作用。結果如圖14所示。由圖14可知,富里酸純品(日本腐植質物質學會提供)之效果,可大致再現腐植礦(富里酸+礦物質)之效果。 The concentration-dependent ATP consumption enhancing effect of fulvic acid was measured by the same method as in Test Example 3. The result is shown in Figure 14. It can be seen from Figure 14 that the effect of pure fulvic acid (provided by the Japanese Society of Humic Substances) can roughly reproduce the effect of humic minerals (fulvic acid + minerals).

此外,C2C12細胞中粒線體機能,係根據製造業者之說明書,使用XFe24通量分析儀Seahorse Bioscience(North Billerica,MA)進行分析。簡潔而言,將C2C12以30,000 cells/well之濃度接種至專用的24孔盤上並培養一晚。此外,富里酸及腐植礦係以添加1mM丙酮酸、2mM谷胺醯胺之專用介質所成介質(以下,稱為基本介質)溶解。載體表示基本介質。至少在測定前40分鐘,將介質交換為基本介質。為了以質子洩漏評估OCR,故藉由寡黴素(ATP合成酶抑制劑)、FCCP(粒線體解耦劑)、及魚藤酮/抗黴素A(呼吸抑制劑)連續處理,從而即時監測氧消耗比(OCR,pmol/分)。結果如圖15及16所示。由圖15及16可知,0.01%富里酸純品及0.01%腐植礦中任一者,皆可增強備用呼吸能(spare respiration capacity)。 In addition, mitochondrial function in C2C12 cells was analyzed using XFe24 flux analyzer Seahorse Bioscience (North Billerica, MA) according to the manufacturer's instructions. Briefly, C2C12 was inoculated onto a dedicated 24-well plate at a concentration of 30,000 cells/well and cultured overnight. In addition, fulvic acid and humic minerals were dissolved in a special medium (hereinafter referred to as the basic medium) with the addition of 1mM pyruvic acid and 2mM glutamine. Carrier means the base medium. At least 40 min before the assay, the medium was exchanged for basic medium. In order to assess OCR by proton leakage, oxygen was monitored in real time by sequential treatment with oligomycin (ATP synthase inhibitor), FCCP (mitochondrial decoupler), and rotenone/antimycin A (respiratory inhibitor). Consumption ratio (OCR, pmol/min). The results are shown in Figures 15 and 16. It can be seen from Figures 15 and 16 that either 0.01% pure fulvic acid or 0.01% humic ore can enhance spare respiration capacity.

由此等結果可知,富里酸及腐植礦,可抑制ATP的合成,間接刺激介由GLUT之醣類運輸,非在粒線體呼吸之有氧代謝途徑,而係導入無氧代謝途徑。藉此,可認為係富里酸及腐植礦作為弱解耦劑運作,從而增加粒線體生物合成。結果可知,如體內之ATP/ADP比之數據表示,可觀察到強力的新陳代謝。 From these results, it can be known that fulvic acid and humic minerals can inhibit the synthesis of ATP and indirectly stimulate the transport of sugars through GLUT, not in the aerobic metabolic pathway of mitochondrial respiration, but in the anaerobic metabolic pathway. From this, it can be considered that fulvic acid and humic minerals act as weak decoupling agents, thereby increasing mitochondrial biosynthesis. As a result, it was found that strong metabolism was observed as indicated by the data of ATP/ADP ratio in vivo.

試驗例11:腐植礦之分析結果 Test Example 11: Analysis Results of Humic Mine

(試料調製) (sample preparation)

試料之製作方法:攪拌試料以進行分析。在250mL廣口瓶加入少量之腐植礦粉末(以下,稱為試料)及少量之精製水,攪拌均勻使其溶解。進一步一點一滴加入少量之試料及精製水,攪拌均勻使其溶解。重複此動作使其成為60%(60g/100mL)溶液後,放入轉子,使用磁力攪拌器,在20℃下攪拌24小時。將24小時攪拌後之溶液移至離心管,離心分離(2500rpm×10分:2回),收集所得上清液,將其作為試驗溶液進行分析。 Preparation method of the sample: Stir the sample for analysis. Add a small amount of humic mineral powder (hereinafter referred to as the sample) and a small amount of purified water into a 250mL jar, stir evenly to dissolve it. Further, add a small amount of sample and purified water drop by drop, stir evenly to dissolve. Repeat this action to make a 60% (60g/100mL) solution, put it into the rotor, and stir at 20°C for 24 hours using a magnetic stirrer. The solution stirred for 24 hours was transferred to a centrifuge tube, centrifuged (2500 rpm×10 minutes: 2 times), and the resulting supernatant was collected and analyzed as a test solution.

富里酸分餾:為了製作鹼性可溶物,關於60%溶液,係放入氫氧化鈉,使其相當0.1M-NaOH溶液(此時,係使用5mL之60%溶液)。使用玻璃纖維濾紙去除沉澱物,過濾液作為鹼性可溶物。為了去除酸性不溶物(富里酸分餾的製作),係對於鹼性可溶物加入鹽酸使pH=2並靜置約12小時,使用玻璃纖維濾紙去除酸性不溶物。所得過濾液作為富里酸分餾進行分析。 Fractional distillation of fulvic acid: In order to produce alkaline solubles, sodium hydroxide is added to the 60% solution to make it equivalent to a 0.1M-NaOH solution (at this time, 5mL of the 60% solution is used). Use glass fiber filter paper to remove precipitates, and the filtrate is used as alkaline soluble matter. In order to remove the acidic insoluble matter (production of fulvic acid fractionation), add hydrochloric acid to the alkaline soluble matter to make the pH = 2 and let it stand for about 12 hours, then use glass fiber filter paper to remove the acidic insoluble matter. The resulting filtrate was analyzed as a fulvic acid fraction.

紅外線吸收(FT-IR):傅立葉變換紅外分光光度法:試料在105℃下乾燥2小時(液體試料直到乾燥為止),以重量法進行分析。乾燥後之試料在600℃下升溫2小時,以重量法進行分析。使用純化之Supelco社製DAX-8樹脂,吸附4%溶液中之樹脂吸附性有機物,之後,以鹼性溶液解吸後,藉由離子交換樹脂將不要之鹽類去除,去除者作為分析試料,藉由FT-IR法取得紅外吸收光譜。 Infrared Absorption (FT-IR): Fourier Transform Infrared Spectrophotometry: Samples were dried at 105°C for 2 hours (liquid samples until dry), and analyzed gravimetrically. The dried sample was heated at 600° C. for 2 hours, and analyzed by gravimetric method. Use the purified DAX-8 resin manufactured by Supelco to absorb the resin-adsorbable organic matter in the 4% solution, and then desorb with the alkaline solution, remove the unnecessary salts with the ion-exchange resin, and use the removed one as the analysis sample. The infrared absorption spectrum was obtained by the FT-IR method.

將富里酸(三維螢光分光光度計方法)試料放入測量單元,取得三維激發-螢光光譜,基於腐植質物質表示螢光之波長全域之螢光強度之總和進行定量。又,由於螢光特性之標準物質係使用棕色森林土壤富里酸(日本腐植質物質學會頒布),故所得之值係相對於棕色森林土壤富里酸之螢光 特性為規格化之值。此外,以10μg/L硫酸奎寧之激發波長345nn、螢光波長455nm之螢光強度作為10QSU算出相對螢光強度(QSU),由上述波長範圍之螢光強度之總和及高峰值,計算試料之相對螢光強度(QSU)。 Put the fulvic acid (three-dimensional fluorescence spectrophotometer method) sample into the measurement unit, obtain the three-dimensional excitation-fluorescence spectrum, and perform quantification based on the sum of the fluorescence intensity of the entire wavelength range of the fluorescence expressed by the humic substances. In addition, since the standard material of the fluorescence characteristic is the brown forest soil fulvic acid (promulgated by the Japanese Society of Humic Substances), the obtained value is relative to the fluorescence of the brown forest soil fulvic acid Properties are normalized values. In addition, the relative fluorescence intensity (QSU) was calculated by taking the fluorescence intensity of 10 μg/L quinine sulfate at an excitation wavelength of 345nm and a fluorescence wavelength of 455nm as 10QSU, and calculated the relative fluorescence intensity (QSU) from the sum and peak value of the fluorescence intensity in the above wavelength range. Relative fluorescence intensity (QSU).

(結果) (result)

關於光學特性之註釋:如分析方法所記載,係使用螢光特性之標準物質之棕色森林土壤富里酸(日本腐植質物質學會頒布)時之定量值。因此,將不同產地之富里酸作為標準使用時,由於分子構造不同會導致光學特性(螢光特性)不同,故定量值會相異。 Notes on optical properties: As stated in the analysis method, it is the quantitative value when using the standard substance of fluorescent properties, brown forest soil fulvic acid (promulgated by the Japanese Society of Humic Substances). Therefore, when fulvic acid produced in different places is used as a standard, the quantitative value will be different due to the difference in optical properties (fluorescent properties) due to the difference in molecular structure.

結果如圖17及18所示。此外,表2及3表示相對螢光強度(QSU)。激發波長260nm、螢光波長440nm附近可看到有高峰。紅外吸收光譜(FT-IR),可確認到富里酸特有之各種官能基(圖17),三維螢光光譜,在富里酸特有之波長域顯示自家螢光(圖18)。藉此,可確定本試料所含有機物係富里酸。此外,與紅外吸收光譜之文獻值比較,可發現比起日本腐植質物質學會所頒布之棕色森林土壤富里酸,有羧基較少而芳香族較多之傾向。 The results are shown in Figures 17 and 18. In addition, Tables 2 and 3 show relative fluorescence intensity (QSU). A peak can be seen near the excitation wavelength of 260nm and the fluorescence wavelength of 440nm. Infrared absorption spectrum (FT-IR) can confirm various functional groups unique to fulvic acid (Figure 17), and three-dimensional fluorescence spectrum shows autofluorescence in the wavelength range unique to fulvic acid (Figure 18). From this, it can be determined that the organic substance contained in this sample is fulvic acid. In addition, compared with the literature value of infrared absorption spectrum, it can be found that compared with the brown forest soil fulvic acid promulgated by the Japanese Society of Humic Substances, it has a tendency to have fewer carboxyl groups and more aromatics.

Figure 108103346-A0202-12-0020-2
Figure 108103346-A0202-12-0020-2

Figure 108103346-A0202-12-0020-3
表中「%」係表示試料濕重量中之含量。
Figure 108103346-A0202-12-0020-3
"%" in the table means the content in the wet weight of the sample.

統計分析 Statistical Analysis

2組間之統計差異,使用學生的t檢定進行分析。當P值未達0.05時可判斷出存在顯著差異。 The statistical difference between the two groups was analyzed using Student's t test. A significant difference was judged to exist when the P value was less than 0.05.

Claims (6)

一種包含富里酸與複數種礦物質的組成物的使用,其特徵係用在生活習慣病之改善或預防用食品組成物的製造中,其中該食品組成物不包含喜來芝或海洋腐殖質的水溶劑提取物。 Use of a composition containing fulvic acid and plural minerals, characterized in that it is used in the manufacture of a food composition for the improvement or prevention of lifestyle-related diseases, wherein the food composition does not contain shilajit or marine humus solvent extract. 如申請專利範圍第1項所記載之使用,其中,前述生活習慣病,係選自糖尿病、胰島素阻抗性、高脂血症、肥胖、脂肪肝、運動障礙症候群、肌肉減少症、及惡病體質所成群中至少1種。 As described in item 1 of the patent application, wherein the aforementioned lifestyle-related diseases are selected from diabetes, insulin resistance, hyperlipidemia, obesity, fatty liver, dyskinesia syndrome, sarcopenia, and cachexia At least 1 species in all groups. 一種包含富里酸與至少一種礦物質的組成物的使用,其特徵係用在肝機能改善用食品組成物的製造中。 The use of a composition comprising fulvic acid and at least one mineral is characterized in that it is used in the manufacture of a food composition for improving liver function. 一種包含富里酸與至少一種礦物質的組成物的使用,其特徵係用在抗疲勞用食品組成物的製造中,其中該食品組成物的有效成分僅包含該富里酸與至少一種礦物質。 The use of a composition comprising fulvic acid and at least one mineral is characterized in that it is used in the manufacture of an anti-fatigue food composition, wherein the active ingredients of the food composition only contain the fulvic acid and at least one mineral. 一種包含富里酸與至少一種礦物質的組成物的使用,其特徵係用在肌肉增強用食品組成物的製造中,其中該食品組成物的有效成分僅包含該富里酸與至少一種礦物質。 The use of a composition comprising fulvic acid and at least one mineral is characterized in that it is used in the manufacture of a food composition for muscle enhancement, wherein the active ingredients of the food composition only contain the fulvic acid and at least one mineral. 一種包含富里酸與至少一種礦物質的組成物的使用,其特徵係用在粒線體激活劑的製造中。 Use of a composition comprising fulvic acid and at least one mineral is characterized in the manufacture of a mitochondrial activator.
TW108103346A 2018-01-29 2019-01-29 Food composition for improvement or prevention of lifestyle-related diseases TWI810239B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018012270 2018-01-29
JP2018-012270 2018-01-29

Publications (2)

Publication Number Publication Date
TW201934021A TW201934021A (en) 2019-09-01
TWI810239B true TWI810239B (en) 2023-08-01

Family

ID=67395001

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108103346A TWI810239B (en) 2018-01-29 2019-01-29 Food composition for improvement or prevention of lifestyle-related diseases

Country Status (3)

Country Link
JP (1) JP7038424B2 (en)
TW (1) TWI810239B (en)
WO (1) WO2019146790A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021042151A (en) * 2019-09-10 2021-03-18 株式会社東洋新薬 Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101744844A (en) * 2009-12-14 2010-06-23 昆明理工大学 Fulvic acid or sodium fulvate substance with hypoglycemic function
KR20120108797A (en) * 2011-03-25 2012-10-05 허교 Anti-hepatic toxicity of fulvic acid against hepatic injury
JP2013032298A (en) * 2011-08-01 2013-02-14 Kinki Univ Aqueous solvent extract of marine humus and its application
WO2015179675A1 (en) * 2014-05-21 2015-11-26 Natreon, Inc. Chromium-containing compositions for improving endothelial function and cardiovascular health
JP2017530980A (en) * 2014-10-02 2017-10-19 ナトレオン,インコーポレイテッド Use of Shilajit to promote muscle build-up and repair and treat disorders related to collagen and related proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101744844A (en) * 2009-12-14 2010-06-23 昆明理工大学 Fulvic acid or sodium fulvate substance with hypoglycemic function
KR20120108797A (en) * 2011-03-25 2012-10-05 허교 Anti-hepatic toxicity of fulvic acid against hepatic injury
JP2013032298A (en) * 2011-08-01 2013-02-14 Kinki Univ Aqueous solvent extract of marine humus and its application
WO2015179675A1 (en) * 2014-05-21 2015-11-26 Natreon, Inc. Chromium-containing compositions for improving endothelial function and cardiovascular health
JP2017530980A (en) * 2014-10-02 2017-10-19 ナトレオン,インコーポレイテッド Use of Shilajit to promote muscle build-up and repair and treat disorders related to collagen and related proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 STOHS, Sidney J. et al., "Safety and Efficacy of Shilajit (Mumie, Moomiyo), Phytother Res, 2014, vol. 28, pages 475-479. *

Also Published As

Publication number Publication date
WO2019146790A1 (en) 2019-08-01
JP7038424B2 (en) 2022-03-18
JPWO2019146790A1 (en) 2021-01-14
TW201934021A (en) 2019-09-01

Similar Documents

Publication Publication Date Title
US20110038959A1 (en) Plant-origin drug for preventing or improving hyperuricemia
JP2014037399A (en) Anti-glycation agent and method for producing the same
Wang et al. Chicory (Cichorium intybus L.) inhibits renal reabsorption by regulating expression of urate transporters in fructose-induced hyperuricemia
TWI810239B (en) Food composition for improvement or prevention of lifestyle-related diseases
Chen et al. The effect of lipid metabolism regulator anthocyanins from Aronia melanocarpa on 3T3-L1 preadipocytes and C57BL/6 mice via activating AMPK signaling and gut microbiota
WO2023199967A1 (en) eNAMPT INCREASING AGENT, SIRTUIN ACTIVATION OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENESCENT CELL INHIBITOR
WO2011150229A2 (en) Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
WO2022220265A1 (en) Sirtuin or klotho activator or expression enhancer, nad+ increasing agent, and senolytic agent
JP2013107852A (en) Maillard reaction inhibitor
KR100971039B1 (en) Composition for Prevention or Treatment of Osteoporosis Comprising Rubus Coreanus Miquel Extract
JP7403446B2 (en) autophagy activator
KR101515842B1 (en) Pharmaceutical composition for prevention and treatment of hyperglycemia and type 2 diabetes comprising mineral extract of deep sea water
Ilegbedion et al. Evaluation of MSG on electrolyte balance and histology of gastroesophageal mucosa
CN108349877B (en) Novel citric acid derivatives
KR20070068837A (en) Extracts from the seed of rosa multiflora for inhibiting the differentiation of adipocytic cells
Aitani et al. Effect of an extract from evening-primrose seeds on postprandial blood glucose level and its active components
JP7253642B1 (en) Oral composition for suppressing elevation of blood sugar level, oral composition for suppressing AGE production, supplement, functional food and pharmaceutical composition
JP7373622B2 (en) Composition for inhibiting muscle atrophy and composition for suppressing expression of a gene causing muscle atrophy
JP7433337B2 (en) Platelet-derived growth factor (PDGF) - BB production enhancer, stem cell stabilizer containing the same, and skin anti-aging agent containing the same
JP5294194B2 (en) Drugs for cerebrovascular dementia
JP6003018B2 (en) Hepatoprotective agent, pharmaceutical composition, and composition for protecting cells, etc.
KR102257836B1 (en) Pharmaceutical composition comprising the extracts from the branch of Taxillus yadoriki for preventing or treating inflammatory disease
JP2011144147A (en) Gaba-rich tomato-derived composition having anti-stress effect
JP6847511B2 (en) Fat accumulation inhibitor and foods and drinks containing it
WO2016073843A2 (en) Enhanced expression of mtor and inhibited expression of myostatin in skeletal muscle cells